Mr. Battley Appointed to Board of Directors of
MedReleaf Australia
TSX | NYSE: ACB
EDMONTON, Dec. 21, 2019 /PRNewswire/ - Aurora Cannabis
Inc. (the "Company" or "Aurora") (NYSE │ TSX: ACB), the
Canadian company defining the future of cannabis worldwide,
announces a change to the Executive Team. Cam Battley has stepped down as Chief Corporate
Officer effective December 20, 2019.
Mr. Battley joined Aurora in 2016, serving a number of senior
roles critical to the success of the company in its early years
before being named Chief Corporate Officer in 2018. Mr. Battley has
been instrumental in Aurora's international growth, serving as a
powerful advocate and corporate voice in support of global
acceptance.
Mr. Battley has earned the reputation as a formidable leader and
advocate in Canada and beyond.
With a clear passion for cannabis advocacy, Aurora is grateful for
his contributions to the company's growth and role as a global
medical cannabis leader. As the Canadian cannabis industry
evolves, Aurora continues to enhance its executive team to be fit
for the longevity of the industry in Canada and beyond.
"Our roots run deep, and Cam has been an integral part of the
development, growth and expansion of Aurora," says Terry Booth, CEO of Aurora. "We are grateful for
Cam's leadership and passion over his many years with Aurora.
I am sure Cam will be successful as he moves on to tackle
Australia."
Mr. Battley was appointed to MedReleaf Australia's Board in
November of 2019. This appointment has been approved by
Australia's Federal Office of Drug
Control. MedReleaf Australia is a privately held medical cannabis
company established in 2016, based in Brisbane, Queensland. MedReleaf Australia is fully
licensed to cultivate, manufacture, import and sell medical
cannabis. Aurora holds a 10% stake as well as 50% voting rights in
MedReleaf Australia. Australia has
seen dramatic growth in the medical cannabis space over the last 18
months from less than 500 patients in June of 2018 to over 24,000
as of November 2019.
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 625,000 kg per
annum and sales and operations in 25 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high-quality consistent product. Designed to be replicable and
scalable globally, our production facilities are designed to
produce cannabis at significant scale, with high quality,
industry-leading yields, and low-per gram production costs. Each of
Aurora's facilities is built to meet European Union Good
Manufacturing Practices ("EU GMP") standards. Certification has
been granted to Aurora's first production facility in Mountain View
County, the MedReleaf Markham facility, and its wholly owned
European medical cannabis distributor Aurora Deutschland. All
Aurora facilities are designed and built to the EU GMP
standard.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 17 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern
Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia,
HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs,
Whistler, Chemi Pharmaceutical, and Hempco – Aurora is
distinguished by its reputation as a partner and employer of choice
in the global cannabis sector, having invested in and established
strategic partnerships with a range of leading innovators,
including: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd.
(ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom
Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH),
Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave
Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group
(private). Aurora's Common Shares trade on the TSX and NYSE under
the symbol "ACB", and is a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. These forward-looking statements are only
predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions, estimates and
assumptions of management in light of management's experience and
perception of historical trends, current conditions and expected
developments at the date the statements are made, such as current
and future market conditions, the current and future regulatory
environment and future approvals and permits. Forward-looking
statements are subject to a variety of risks, uncertainties and
other factors that management believes to be relevant and
reasonable in the circumstances could cause actual events, results,
level of activity, performance, prospects, opportunities or
achievements to differ materially from those projected in the
forward-looking statements, including general business and economic
conditions, changes in laws and regulations, product demand,
changes in prices of required commodities, competition and other
risks, uncertainties and factors set out under the heading "Risk
Factors" in the Company's annual information form dated
September 10, 2019 (the "AIF") and
filed with Canadian securities regulators available on the
Company's issuer profile on SEDAR at www.sedar.com. The Company
cautions that the list of risks, uncertainties and other factors
described in the AIF is not exhaustive and other factors could also
adversely affect its results. Readers are urged to consider the
risks, uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-announces-change-to-executive-team-cam-battley-steps-away-from-his-role-as-chief-corporate-officer-300978718.html
SOURCE Aurora Cannabis Inc.